Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gut microbiota and hormone therapy outcomes in estrogen receptor-positive breast cancer
NL-OMON20717Not yet recruiting
- Sponsor
- Maastricht University Medical Center+
- Start
- Sep 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label trial of tamoxifen in breast cancer (2 cohorts), sponsored by Maastricht University Medical Center+. Planned start Sep 2017; status: not yet recruiting.
02
Drugs
tamoxifen
03
Conditions
breast cancer
Beyond the preview
Go deeper on NL-OMON20717.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON20717.